Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EHA 2020 | BCMA-targeting therapies in myeloma

Rakesh Popat • 11 Jun 2020

EHA 2020

Multiple Myeloma Antibodies Belantamab mafodotin CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel Teclistamab

CARTITUDE-1 DREAMM-2 KarMMa

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of the University College London Hospitals, London, UK, highlights B-cell maturation antigen (BCMA) targeting therapies in multiple myeloma including belantamab mafodotin, a BCMA targeting antibody-drug conjugate, as well as ciltacabtagene autoleucel (cilta-cel) and idecabtagene vicleucel (ide-cel), two different BCMA CAR-T cell therapies. Dr Popat also highlights novel BiTEs presented at EHA 2020 such as teclistamab, a BCMA x CD3 bispecific antibody investigated in a Phase I dose-escalation study. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

The optimal sequencing of CAR-T and other immunotherapies in multiple myeloma

Rakesh Popat • 16 Feb 2024

'Clinical case discussions' session rundown: HLH/MAS, aseptic meningitis, & CAR-NK cells in MM

Rakesh Popat • 16 Feb 2024

Selecting patients with myeloma for CAR-T: important clinical considerations

Rakesh Popat • 16 Feb 2024

The potential of CELMoDs for the treatment of R/R multiple myeloma

Rakesh Popat • 10 Dec 2023

Related Videos

Investigating production failure and out-of-specification production of CAR T-cell therapeutics

Nina Worel • 25 Apr 2024

Using MRD to accelerate drug approval in multiple myeloma

Karthik Ramasamy • 28 Apr 2024

Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial

Roberto Mina • 23 Apr 2024

CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma

Eden Biltibo • 15 Apr 2024